IFP Advisors Inc decreased its stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 31.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,022 shares of the company’s stock after selling 3,237 shares during the quarter. IFP Advisors Inc’s holdings in Teva Pharmaceutical Industries were worth $151,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently added to or reduced their stakes in the company. PointState Capital LP acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth about $161,826,000. Point72 Asset Management L.P. acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth about $90,746,000. Renaissance Technologies LLC raised its position in shares of Teva Pharmaceutical Industries by 348.1% during the second quarter. Renaissance Technologies LLC now owns 4,036,863 shares of the company’s stock worth $98,177,000 after purchasing an additional 3,135,900 shares during the period. Caisse DE Depot ET Placement DU Quebec raised its position in shares of Teva Pharmaceutical Industries by 116.1% during the second quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,354,508 shares of the company’s stock worth $57,262,000 after purchasing an additional 1,264,900 shares during the period. Finally, Cacti Asset Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth about $10,911,000. 61.66% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms have recently commented on TEVA. Mizuho reaffirmed a “buy” rating and set a $28.00 price target on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 16th. Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a report on Monday. Maxim Group reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, November 1st. Royal Bank of Canada set a $22.00 price objective on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, November 2nd. Finally, Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, November 7th. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $21.94.
NYSE:TEVA traded up $0.05 during mid-day trading on Monday, hitting $21.59. 8,370,021 shares of the stock were exchanged, compared to its average volume of 12,493,834. The stock has a market cap of $21.90 billion, a P/E ratio of 5.49, a PEG ratio of 6.49 and a beta of 0.74. The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 1.75. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $14.05 and a fifty-two week high of $25.96.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.11. The business had revenue of $4.53 billion during the quarter, compared to analysts’ expectations of $4.54 billion. Teva Pharmaceutical Industries had a positive return on equity of 21.83% and a negative net margin of 54.67%. The firm’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same period last year, the firm posted $1.00 EPS. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.82 EPS for the current year.
Teva Pharmaceutical Industries Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: Coverage Ratio
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.